278 related articles for article (PubMed ID: 31361865)
1. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
[TBL] [Abstract][Full Text] [Related]
2. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury.
Wendte J; Voss G; VanOverschelde B
Am J Health Syst Pharm; 2016 Apr; 73(8):563-7. PubMed ID: 27045068
[TBL] [Abstract][Full Text] [Related]
3. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
Smith AR; Dager WE; Gulseth MP
Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
[TBL] [Abstract][Full Text] [Related]
4. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
5. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
6. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers.
Spiller HA; Mowry JB; Aleguas A; Griffith JR; Goetz R; Ryan ML; Bangh S; Klein-Schwartz W; Schaeffer S; Casavant MJ
Ann Emerg Med; 2016 Feb; 67(2):189-95. PubMed ID: 26298448
[TBL] [Abstract][Full Text] [Related]
7. Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation.
Lin SY; Kuo CH; Yeh SJ; Tsai LK; Liu YB; Huang CF; Tang SC; Jeng JS
Clin Pharmacol Ther; 2020 Jan; 107(1):278-286. PubMed ID: 31376150
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
9. The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.
Brendel LC; Dobler F; Hessling G; Michel J; Braun SL; Steinsiek AL; Groha P; Eckl R; Deisenhofer I; Hyseni A; Roest M; Ott I; Steppich B
J Interv Card Electrophysiol; 2017 Sep; 49(3):237-244. PubMed ID: 28735423
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
[TBL] [Abstract][Full Text] [Related]
12. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions.
Faust AC; Kanyer D; Wittkowsky AK
Am J Health Syst Pharm; 2016 Dec; 73(24):2037-2041. PubMed ID: 27919873
[TBL] [Abstract][Full Text] [Related]
13. Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.
Wada S; Toyoda K; Sato S; Matsuki T; Okata T; Kumamoto M; Tagawa N; Inoue M; Okamoto A; Ihara M; Kitazono T; Miyata T; Koga M
Circ J; 2018 Oct; 82(11):2872-2879. PubMed ID: 30210082
[TBL] [Abstract][Full Text] [Related]
14. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
15. Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside.
Poredos P; Jezovnik MK
Curr Drug Targets; 2018; 19(6):577-580. PubMed ID: 25981607
[TBL] [Abstract][Full Text] [Related]
16. Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
Towers W; Nguyen SN; Ruegger MC; Salazar E; Donahue KR
Ann Pharmacother; 2022 Jun; 56(6):656-663. PubMed ID: 34541895
[TBL] [Abstract][Full Text] [Related]
17. Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care.
Gulilat M; Tang A; Gryn SE; Leong-Sit P; Skanes AC; Alfonsi JE; Dresser GK; Henderson SL; Rose RV; Lizotte DJ; Teft WA; Schwarz UI; Tirona RG; Kim RB
Can J Cardiol; 2017 Aug; 33(8):1036-1043. PubMed ID: 28754389
[TBL] [Abstract][Full Text] [Related]
18. Apixaban and rivaroxaban in patients with cerebral venous thrombosis.
Covut F; Kewan T; Perez O; Flores M; Haddad A; Daw H
Thromb Res; 2019 Jan; 173():77-78. PubMed ID: 30481600
[No Abstract] [Full Text] [Related]
19. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
Macedo KA; Tatarian P; Eugenio KR
Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
[TBL] [Abstract][Full Text] [Related]
20. Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery.
Hakeam HA; Alkhani M; Alyahya Z; Alawaji Z; Ofori S
J Cardiovasc Pharmacol; 2021 Dec; 78(6):867-874. PubMed ID: 34882113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
